Tough Virus

[Guest guest]

HCV ain't so bad. Here's a paper that was published by the American Society for Microbiology. Please note that one of the authors is from AVI Biopharma Inc., the company that I believe is going to change the way HCV is treated. VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice Sven Enterlein,1, L. Warfield,2, Dana L. Swenson,2 A. Stein,3 Jeffery L. ,2 C. Gamble,2 D. Kroeker,3 L. Iversen,3 Sina Bavari,2* and Elke M¨¹hlberger1* Department of Virology,

Philipps-University Marburg, Hans-Meerwein-Str. 3, 35043 Marburg, Germany,1 U.S. Army Medical Research Institute of Infectious Diseases, Frederick, land 21702-5011,2 AVI BioPharma Inc., Corvallis, Oregon3 Received 29 June 2005/ Returned for modification 5 August 2005/ Accepted 3 January 2006 Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic

for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the

potential to control EBOV infection and are promising therapeutic candidates. elizabethnv1 <elizabethnv1@...> wrote: Thanks anne , I will just have to keep my eyes open for anything new on the horizon ,lol RE: Doctor on Long> Island> > > Thank you for the listing of doctors; however, I> was really interested in personal recommendations. > I have a listing of doctors covered under my plan,> but was hoping for more information from patients> treated by specific doctors rather than a listing of> all doctors in the metro NY area.> > I am planning on contacting Dr. Bernstein's office> today to set up an appointment. I am hoping that I>

am making a good choice.> > Thank you so much for your effort. Be well.> > > > Jackie > > ---------------------------------> > Use Photomail to share photos without annoying> attachments. > > It's a pleasure having you join in our> conversations. We hope you have found the support> you need with us. > > If you are using email for your posts, for easy> access to our group, just click the link--> Hepatitis C/> > Happy Posting > > > >